Target- |
MechanismInsulin sensitizers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Pilot Study of the Effects of GC811007 Administration on Copper and Trace Metal Metabolism in Non-diabetic Subjects and Patients with Type 2 Diabetes Mellitus: a randomized, double-blind, placebo-controlled trial in adult males with Type 2 diabetes mellitus and non-diabetic subjects to measure the effects on urinary copper, zinc and iron excretion.
Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.
A Single Center, Randomized, Double-Blind, Single-Dose, 2-Way Crossover, Dose Escalation Study of the Pharmacokinetics and Pharmacodynamics of PX811019 Compared with triethylenetetramine dihydrochloride in Normal Healthy Volunteers to compare the pharmacokinetic (PK) profiles: to determine the dosing relationship of PX811019 relative to triethylenetetramine dihydrochloride and to characterize the pharmacodynamic profile of urinary copper excretion in response to the study drug.
100 Clinical Results associated with Protemix Corp. Ltd.
0 Patents (Medical) associated with Protemix Corp. Ltd.
100 Deals associated with Protemix Corp. Ltd.
100 Translational Medicine associated with Protemix Corp. Ltd.